Skip to content
Markets News
Stocks1 min read

CRISPR Therapy Cuts Triglycerides 63% in Phase 1b Cohort

Makkler Newsroom
November 9, 2026 · Based on reporting by GlobeNewswire

The experimental CTX310 treatment lowered triglycerides and ANGPTL3 in patients with severe hypertriglyceridemia, based on data from 10 participants.

Key takeaways

  • CTX310 reduced triglycerides by a mean 63% at Day 30 in 10 participants.
  • The company reported no treatment-related serious adverse events or clinically relevant liver enzyme elevations.

CRISPR Therapeutics reported that its experimental CTX310 treatment cut triglycerides by a mean 63% at Day 30 in 10 patients with severe hypertriglyceridemia. The Phase 1b results were presented at the American Heart Association Scientific Sessions.

The company said ANGPTL3 levels fell by a mean 65%. Participants had a median baseline triglyceride level above 1,000 mg/dL.

CRISPR Therapeutics reported no serious adverse events related to treatment and no clinically relevant elevations in liver enzymes. One participant had a Grade 2 infusion-related reaction that resolved; the infusion was completed.

As of Monday 14:35 UTC, CRISPR Therapeutics shares traded at $49.98, down 0.18% since the previous close.

Topics
CRSPCTX310

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.